Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | SLC22A2 | O15244 | 6/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 6/20 | 0.56 |
| ▸ | SLC22A3 | O75751 | 6/20 | 0.56 |
| ▸ | PLAU | P00749 | 6/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 5/20 | 0.56 |
| ▸ | HTR3B | O95264 | 5/20 | 0.56 |
| ▸ | HTR3A | P46098 | 5/20 | 0.56 |
| ▸ | HTR3D | Q70Z44 | 5/20 | 0.56 |
| ▸ | HTR3C | Q8WXA8 | 5/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | NOS3 | P29474 | 2/20 | 0.53 |
| ▸ | NOS1 | P29475 | 2/20 | 0.53 |
| ▸ | NOS2 | P35228 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11099753 | 0.97 | PLG (0.95) | PLGPOLBSLC22A2SLC22A1SLC22A3 | |
| SCHEMBL1703486 | 0.80 | PLG (0.67) | PLGPOLBSLC22A2SLC22A1SLC22A3 | |
| Phenylguanidine SCHEMBL29091382 | 0.75 | SLC22A2 (0.71) | PLGPOLBSLC22A2SLC22A1SLC22A3 | |
| SCHEMBL8932568 | 0.74 | PLG (0.58) | PLGPOLBHTR3EHTR3BHTR3A | |
| Phenylguanidine SCHEMBL467577 | 0.72 | SLC22A2 (1.00) | PLGPOLBSLC22A2SLC22A1SLC22A3 | |
| SCHEMBL1738380 | 0.72 | POLB (0.82) | PLGPOLBSLC22A2SLC22A1SLC22A3 | |
| Pyraxinine SCHEMBL2456850 | 0.72 | HTR3E (1.00) | PLGPOLBSLC22A2SLC22A1SLC22A3 | |
| SCHEMBL23411272 | 0.71 | PLG (0.53) | PLGPOLBSLC22A2SLC22A1SLC22A3 | |
| SCHEMBL6213542 | 0.71 | ALDH1A1 (0.64) | PLGNOS3NOS1NOS2CYP2D6 | |
| SCHEMBL6213539 | 0.71 | ALDH1A1 (0.64) | PLGNOS3NOS1NOS2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023068423-A1 | COMPLEX ANTICANCER DRUG COMPOSITION USING PHOTOREACTIVITY AND PREPARATION METHOD THEREFOR | 닥터아이앤비(주) | 2023-04-27 | — | — | WO | claimed |
| EP-1838696-B1 | NOVEL CYANOGUANIDINE COMPOUNDS | LEO PHARMA AS (DK) | 2016-03-09 | — | — | EP | claimed |
| CN-103073486-A | Polymorphs of N-(6-(4-chlorophenyloxy)hexyl)-N'-cyano-N\"-(4-pyridyl)guanidine, and preparation methods and applications thereof | TIANJIN HEMEI BIOLOG TECHNOLOGY CO LTD | 2013-05-01 | — | — | CN | claimed |
| EP-1838696-A1 | NOVEL CYANOGUANIDINE COMPOUNDS | Leo Pharma A/S (DK) | 2007-10-03 | — | — | EP | claimed |
| WO-2006066584-A1 | NOVEL CYANOGUANIDINE COMPOUNDS | LEO PHARMA A/S (DK) | 2006-06-29 | — | — | WO | claimed |
| EP-1397355-A1 | PYRIDYL CYANOGUANIDINE COMPOUNDS | Leo Pharma A/S (DK) | 2004-03-17 | — | — | EP | claimed |
| CN-1121389-C | Cyanoguanidine as cell proliferation inhibitor | LEO PHARM PROD LTD (DK) | 2003-09-17 | — | — | CN | claimed |
| WO-2002094813-A1 | NOVEL PYRIDYL CYANOGUANIDINE COMPOUNDS | LEO PHARMA A/S (DK) | 2002-11-28 | — | — | WO | claimed |
| CN-1314890-A | Cyanoguanidines as cell proliferation inhibitors | LEO PHARM PROD LTD (DK) | 2001-09-26 | — | — | CN | claimed |
| WO-2023068423-A1 | COMPLEX ANTICANCER DRUG COMPOSITION USING PHOTOREACTIVITY AND PREPARATION METHOD THEREFOR | 닥터아이앤비(주) | 2023-04-27 | — | — | WO | disclosed |
| US-9676721-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2017-06-13 | — | — | US | disclosed |
| EP-1838696-B1 | NOVEL CYANOGUANIDINE COMPOUNDS | LEO PHARMA AS (DK) | 2016-03-09 | — | — | EP | disclosed |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2611778-B1 | GUANIDINE COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20020165201-A1 | Cyanoguanidine prodrugs | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-11-07 | — | — | US | disclosed |
| WO-2002042265-A2 | CYANOGUANIDINE PRODRUGS | LEO PHARMA A/S (DK) | 2002-05-30 | — | — | WO | disclosed |
| US-6346520-B1 | ANTITUMOR AND ANTICARCINOGENIC AGENTS; PSORIASIS | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 2002-02-12 | — | — | US | disclosed |
| US-6346541-B1 | ANTITUMOR AND ANTICARCINOGENIC AGENTS FOR BREAST, LUNG, AND SKIN CANCER | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-02-12 | — | — | US | disclosed |
| CN-1314890-A | Cyanoguanidines as cell proliferation inhibitors | LEO PHARM PROD LTD (DK) | 2001-09-26 | — | — | CN | disclosed |
| CN-1258279-A | Cyanoguanidines as cell proliferation inhibitors | LEO PHARM PROD LTD (DK) | 2000-06-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165201-A1 | Cyanoguanidine prodrugs | CBR1, SIGMAR1, ROR1 | PLG 1800/4885POLB 1563/4885SLC22A2 2992/4885 |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | PLG 671/4885POLB 4109/4885SLC22A2 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.